Company Analysis Apellis Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (23.2 $) is less than fair price (23.47 $)
- The stock's return over the last year (32.65%) is higher than the sector average (-4.01%).
Disadvantages
- Dividends (0%) are below the sector average (0.55%).
- Current debt level 53.08% has increased over 5 years from 39.32%.
- The company's current efficiency (ROE=-93.55%) is lower than the sector average (ROE=104.34%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Apellis Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -11.7% | -16.5% | -0.1% |
| 90 days | 20.5% | -5.8% | 1.2% |
| 1 year | 32.6% | -4% | 18% |
APLS vs Sector: Apellis Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 36.66% over the past year.
APLS vs Market: Apellis Pharmaceuticals, Inc. has outperformed the market by 14.68% over the past year.
Stable price: APLS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: APLS with weekly volatility of 0.63% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (23.2 $) is lower than the fair price (23.47 $).
Price not significantly lower than the fair price: The current price (23.2 $) is slightly lower than the fair price by 1.2%.
5.2. P/E
P/E vs Sector: The company's P/E (-14.97) is lower than that of the sector as a whole (35.84).
P/E vs Market: The company's P/E (-14.97) is higher than that of the market as a whole (-99.49).
5.3. P/BV
P/BV vs Sector: The company's P/BV (17.29) is lower than that of the sector as a whole (254.49).
P/BV vs Market: The company's P/BV (17.29) is lower than that of the market as a whole (71.88).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (5.06) is lower than that of the sector as a whole (127.81).
P/S vs Market: The company's P/S indicator (5.06) is lower than that of the market as a whole (113.77).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-25.96) is higher than that of the sector as a whole (-27.35).
EV/Ebitda vs Market: The company's EV/Ebitda (-25.96) is higher than that of the market as a whole (-78.41).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -14.7% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-14.7%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1802.65%).
6.4. ROE
ROE vs Sector: The company's ROE (-93.55%) is lower than that of the sector as a whole (104.34%).
ROE vs Market: The company's ROE (-93.55%) is lower than that of the market as a whole (-6.24%).
6.6. ROA
ROA vs Sector: The company's ROA (-23.64%) is lower than that of the sector as a whole (-2.2%).
ROA vs Market: The company's ROA (-23.64%) is lower than that of the market as a whole (38.46%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-121.89%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-121.89%) is lower than that of the market as a whole (9.59%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.55%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 4.76% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 20.01.2026 | Watson David O. General Counsel |
Sale | 19.79 | 4 898 | 2 475 |
| 20.01.2026 | Chopas James George Officer |
Purchase | 19.79 | 1 437 | 726 |
| 20.01.2026 | Sullivan Timothy Eugene Officer |
Purchase | 19.79 | 5 723 | 2 892 |
| 20.01.2026 | Baumal Caroline Officer |
Purchase | 19.79 | 3 725 | 1 882 |
| 20.01.2026 | Deschatelets Pascal Officer |
Purchase | 19.79 | 1 799 | 909 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
